Cancer Pain Management — Part 1: Pain Assessment and Classification
Comprehensive pain assessment tools, classification systems, and cancer-specific pain syndromes for systematic evaluation of pain in oncology patients.
Pain Screening
Every patient with cancer should be screened for pain at each clinical encounter. Pain screening is a rapid, standardized process designed to identify patients who require a more detailed pain assessment. Professional oncology and palliative care organizations universally recommend routine pain screening as a fundamental component of quality cancer care.1
Recommended Screening Frequency
| Clinical Setting | Screening Frequency |
|---|---|
| Outpatient oncology visits | Every visit |
| Inpatient admission | On admission, then at least every 8 hours |
| Emergency department | At triage and after each intervention |
| Post-surgical | Per institutional acute pain protocol (typically every 1–4 hours) |
| Palliative care / hospice | Each visit or at least daily for inpatients |
| During active anticancer therapy | At each treatment visit and between cycles as indicated |
A positive screen (any pain reported, or pain intensity above the patient’s acceptable threshold) should trigger a comprehensive pain assessment.
Pain Assessment Tools
Unidimensional Scales
Unidimensional pain scales measure a single dimension of the pain experience — typically intensity. They are useful for rapid screening and for tracking pain intensity over time, but they must be supplemented by a comprehensive assessment to guide treatment decisions.
Numeric Rating Scale (NRS)
The NRS is the most widely used pain intensity scale in adult oncology practice. The patient rates pain on a scale from 0 to 10, where 0 represents “no pain” and 10 represents “worst pain imaginable.” The NRS can be administered verbally, in writing, or by having the patient indicate a number on a visual display.
| NRS Score | Pain Severity Category | Clinical Implication |
|---|---|---|
| 0 | No pain | No analgesic intervention needed for pain |
| 1–3 | Mild pain | Non-opioid analgesics may be sufficient; reassess |
| 4–6 | Moderate pain | Consider opioid-containing regimen; reassess within 24–48 hours |
| 7–10 | Severe pain | Urgent analgesic intervention required; consider rapid opioid titration; reassess within hours |
A change of 2 or more points on the NRS (or approximately 30% reduction) is generally considered a clinically meaningful difference. The minimal clinically important difference (MCID) has been established as approximately 1.3 to 2.0 points depending on the clinical context.2
Visual Analog Scale (VAS)
The VAS consists of a horizontal or vertical line, typically 100 mm in length, anchored at one end by “no pain” and at the other by “worst pain imaginable.” The patient marks a point on the line corresponding to their pain intensity, and the distance from the “no pain” anchor is measured in millimeters. The VAS provides a continuous measure with greater statistical sensitivity than the NRS, but it is slightly more difficult to administer and requires a printed form or device. It is primarily used in research settings but remains valid for clinical use.
Wong-Baker FACES Pain Rating Scale
The FACES scale presents a series of six cartoon faces ranging from a smiling face (indicating no pain, scored 0) to a crying face (indicating the worst pain, scored 10). Originally developed for pediatric patients aged 3 years and older, it is also valuable for adult patients with cognitive impairment, language barriers, or low health literacy. The patient selects the face that best represents their current pain experience. Scores correlate with NRS values at the corresponding anchor points (0, 2, 4, 6, 8, 10).3
FLACC Scale (Face, Legs, Activity, Cry, Consolability)
The FLACC is a behavioral observation scale designed for pain assessment in patients who cannot self-report, including preverbal children, patients with severe cognitive impairment, intubated or sedated patients, and patients at end of life who are unable to communicate. Each of the five behavioral categories is scored from 0 to 2, yielding a total score of 0 to 10.
| Category | Score 0 | Score 1 | Score 2 |
|---|---|---|---|
| Face | No particular expression or smile | Occasional grimace or frown; withdrawn, disinterested | Frequent to constant frown, clenched jaw, quivering chin |
| Legs | Normal position or relaxed | Uneasy, restless, tense | Kicking or legs drawn up |
| Activity | Lying quietly, normal position, moves easily | Squirming, shifting back and forth, tense | Arched, rigid, or jerking |
| Cry | No cry (awake or asleep) | Moans or whimpers; occasional complaint | Crying steadily, screams or sobs; frequent complaints |
| Consolability | Content, relaxed | Reassured by occasional touching, hugging, or talking to; distractible | Difficult to console or comfort |
Multidimensional Assessment Tools
Brief Pain Inventory (BPI)
The BPI is the most widely validated multidimensional pain assessment tool in oncology. It measures both pain intensity (four items: pain at its worst, least, average, and current level, each on a 0–10 NRS) and pain interference with daily functions (seven items: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life, each on a 0–10 scale). The BPI can be completed in approximately 5 minutes and is available in validated translations in over 20 languages. Both a long form (BPI-LF) and short form (BPI-SF) exist; the short form is preferred for clinical use.4
Edmonton Symptom Assessment System (ESAS)
The ESAS assesses nine common symptoms in cancer patients including pain, using 0–10 NRS for each. While not a dedicated pain tool, it provides useful context for understanding pain within the broader symptom burden. The ESAS-revised (ESAS-r) includes standardized symptom definitions and improved formatting.
Comprehensive Pain Assessment
A positive pain screen should be followed by a comprehensive pain assessment. The mnemonic OPQRSTUV provides a systematic framework for the clinical pain history. Each element should be documented for every distinct pain complaint, as cancer patients frequently have multiple concurrent pain problems with different mechanisms and optimal treatments.
OPQRSTUV Framework
| Component | Assessment Question | Clinical Relevance |
|---|---|---|
| O — Onset | When did this pain begin? Was onset sudden or gradual? What was happening when it started? | Acute onset may suggest pathological fracture, obstruction, or hemorrhage. Gradual onset is more common with tumor progression. New pain during treatment may indicate treatment-related etiology. |
| P — Provoking / Palliating | What makes the pain worse? What makes it better? Does movement, coughing, eating, or any specific activity affect it? What treatments have been tried and what was their effect? | Movement-related exacerbation suggests somatic nociceptive pain (bone, musculoskeletal). Eating-related pain suggests visceral involvement. Response to prior treatments helps guide further therapy. |
| Q — Quality | What does the pain feel like? (e.g., sharp, dull, aching, burning, shooting, stabbing, cramping, pressure) | Quality descriptors help classify pain mechanism: aching/dull suggests somatic nociceptive; cramping/gnawing suggests visceral; burning/shooting/electric/tingling suggests neuropathic. |
| R — Region / Radiation | Where exactly is the pain? Does it spread or radiate anywhere? Can you point to the area? | Dermatomal radiation suggests nerve root involvement. Pain radiating along a nerve distribution suggests neuropathic mechanism. Diffuse, poorly localized pain suggests visceral origin. |
| S — Severity | Rate your pain on a 0–10 scale: at worst, at best, on average, and right now | Establishes baseline intensity for treatment monitoring. Worst pain and average pain are the most useful for treatment planning. |
| T — Timing | Is the pain constant or intermittent? How often does it occur? How long does each episode last? Is there a pattern (time of day, relation to activities, relation to medication doses)? | Constant background pain requires around-the-clock analgesics. Incident pain (related to specific activities) may benefit from pre-emptive dosing. End-of-dose failure suggests need for dose adjustment or shorter dosing interval. |
| U — Understanding | What do you believe is causing the pain? What is your understanding of your diagnosis and prognosis? What are your concerns about pain or pain treatment? | Addresses psychological and cognitive dimensions. Catastrophizing and fear-avoidance beliefs are associated with worse pain outcomes. Opioid-related fears (addiction, side effects, meaning of needing stronger medications) can be barriers to effective treatment. |
| V — Values | What is your pain goal? What level of pain would be acceptable to you? What functional activities are most important to you? Are there treatments you wish to avoid? | Guides individualized treatment targets. A “pain goal” of 0/10 may not be realistic for all patients; functional goals (e.g., ability to sleep, walk, participate in family activities) are often more meaningful. Cultural and personal values regarding opioid use must be respected. |
Additional Assessment Components
Beyond the OPQRSTUV history, a comprehensive cancer pain assessment should include:
Focused physical examination:
- Inspection and palpation of the painful region
- Neurological examination (sensory testing, motor strength, reflexes, gait) when neuropathic pain is suspected
- Musculoskeletal examination when somatic pain is present
- Assessment for signs of spinal cord compression (a medical emergency): bilateral lower extremity weakness, sensory level, bowel/bladder dysfunction, gait ataxia
Psychosocial assessment:
- Depression and anxiety screening (PHQ-2/PHQ-9, GAD-7)
- Sleep quality
- Functional status (ECOG performance status, Karnofsky)
- Social support and caregiver burden
- Substance use history (past and current)
- Spiritual distress
Review of diagnostic studies:
- Imaging correlated with pain sites (CT, MRI, bone scan, PET-CT)
- Correlation of pain location with known disease extent
Medication history:
- Current and prior analgesic regimen with doses, frequency, and adherence
- Efficacy and side effects of each agent
- Use of adjuvant analgesics
- Use of non-pharmacological strategies
- Over-the-counter and complementary/alternative therapy use
Pain Classification by Mechanism
Cancer pain is classified by its underlying pathophysiological mechanism, as this classification directly informs pharmacological selection. Most cancer patients have mixed pain with contributions from multiple mechanisms, and each component should be identified and targeted.5
Nociceptive Pain
Nociceptive pain results from activation of peripheral nociceptors by tissue damage or inflammation, with an intact somatosensory nervous system. It is subdivided into somatic and visceral types.
Somatic Nociceptive Pain
Somatic pain arises from activation of nociceptors in skin, bone, joint, muscle, or connective tissue. It is typically well-localized and described as aching, sharp, throbbing, or pressure-like.
| Feature | Description |
|---|---|
| Common causes in cancer | Bone metastases, pathological fractures, post-surgical pain, tumor invasion of soft tissue or skin, mucositis |
| Character | Aching, sharp, throbbing, pressure-like; well-localized |
| Aggravating factors | Movement, weight-bearing, palpation (for bone and musculoskeletal sources) |
| Response to opioids | Generally good |
| Key adjuvants | NSAIDs (particularly for bone pain), corticosteroids, bisphosphonates, denosumab, radiation therapy |
Visceral Nociceptive Pain
Visceral pain arises from activation of nociceptors in internal organs, including solid and hollow viscera, their capsules, and the mesentery. It is often poorly localized and may be referred to somatic structures sharing the same segmental innervation.
| Feature | Description |
|---|---|
| Common causes in cancer | Liver capsule distension (hepatic metastases), bowel obstruction, pancreatic cancer, peritoneal carcinomatosis, retroperitoneal tumor mass |
| Character | Deep, diffuse, poorly localized; cramping or colicky (hollow viscus obstruction); constant aching or pressure (solid organ capsule distension); may be referred (e.g., diaphragmatic irritation referred to shoulder) |
| Associated symptoms | Nausea, vomiting, diaphoresis, autonomic changes |
| Response to opioids | Generally good, though hollow viscus colic may respond better to anticholinergics |
| Key adjuvants | Corticosteroids (for capsule distension, obstruction-related edema), anticholinergics (for colic), celiac plexus or superior hypogastric plexus block |
Neuropathic Pain
Neuropathic pain results from damage to or dysfunction of the peripheral or central somatosensory nervous system. It is estimated to contribute to pain in 19% to 39% of cancer patients and is often more difficult to treat than nociceptive pain, typically requiring adjuvant analgesics in addition to or instead of opioids.6
| Feature | Description |
|---|---|
| Common causes in cancer | Tumor compression or infiltration of nerve, plexus, or spinal cord; chemotherapy-induced peripheral neuropathy (CIPN); radiation plexopathy or myelopathy; post-surgical neuropathic pain (post-mastectomy, post-thoracotomy); postherpetic neuralgia |
| Character | Burning, shooting, electric-shock-like, lancinating, tingling, “pins and needles,” numbness; may have paradoxical combination of numbness and pain in same area |
| Clinical signs | Allodynia (pain from normally non-painful stimulus, e.g., light touch), hyperalgesia (exaggerated pain from mildly painful stimulus), hypesthesia, dysesthesia |
| Response to opioids | Partial response; generally requires adjuvant analgesics |
| Key adjuvants | Anticonvulsants (gabapentin, pregabalin), antidepressants (duloxetine, tricyclics), topical agents (lidocaine, capsaicin), interventional procedures |
Neuropathic Pain Screening Tools
When neuropathic pain is suspected, validated screening tools can aid in identification:
- DN4 (Douleur Neuropathique 4): 10-item tool combining patient interview questions and bedside examination; score of 4 or more out of 10 suggests neuropathic pain. Sensitivity approximately 83%, specificity approximately 90%.
- painDETECT: Self-report questionnaire; score of 19 or more suggests neuropathic pain; score of 13–18 is unclear; score of 12 or less makes neuropathic pain unlikely.
- LANSS (Leeds Assessment of Neuropathic Symptoms and Signs): Combines patient-reported symptoms with clinical examination findings; score of 12 or more out of 24 suggests neuropathic pain.
Mixed Pain
Many cancer pain syndromes involve both nociceptive and neuropathic components. For example, a Pancoast tumor may cause somatic bone pain from rib involvement, visceral pain from chest wall invasion, and neuropathic pain from brachial plexus infiltration. Each mechanism should be identified and addressed with appropriate pharmacotherapy.
Cancer-Specific Pain Syndromes
Bone Metastasis Pain
Bone metastases are the most common cause of cancer pain, particularly in patients with breast, prostate, lung, thyroid, and renal cell carcinomas. Up to 75% of patients with bone metastases experience clinically significant pain.
Pathophysiology: Bone pain involves multiple mechanisms including periosteal stretching and mechanical distortion; osteoclast-mediated bone resorption with local acidosis activating acid-sensing ion channels on nociceptors; release of inflammatory mediators (prostaglandins, bradykinin, cytokines, nerve growth factor); and direct tumor-related neuropathic injury to sensory nerves within the bone marrow and periosteum.7
Clinical features:
- Background pain: constant, deep aching pain that gradually worsens over weeks to months
- Incident pain (movement-evoked pain): sharp exacerbation with weight-bearing, movement, or position change; can be severely disabling
- Pathological fracture: sudden severe pain, often with preceding escalating background pain
Management approach:
- Systemic analgesics (analgesic ladder approach)
- NSAIDs (particularly effective for bone pain due to prostaglandin-mediated component)
- Corticosteroids for acute flares and peri-tumor edema
- Bone-modifying agents (bisphosphonates, denosumab)
- Palliative radiation therapy (first-line for localized painful bone metastases)
- Radionuclides for multifocal osteoblastic metastases
- Interventional procedures (vertebroplasty, kyphoplasty for vertebral compression fractures)
- Orthopedic consultation for impending or completed pathological fractures of weight-bearing bones
Visceral Pain Syndromes
Hepatic Capsule Pain
Diffuse hepatic metastases cause pain through distension of the Glisson capsule. Pain is typically in the right upper quadrant or epigastrium, dull and constant, and may be referred to the right shoulder. Corticosteroids (dexamethasone 4–8 mg daily) can reduce peri-tumor edema and capsule distension. Opioids are the mainstay of pharmacological management.
Pancreatic Pain
Pancreatic cancer frequently causes severe epigastric pain radiating to the back due to celiac plexus infiltration. This pain syndrome often involves both visceral nociceptive and neuropathic components. Celiac plexus block or neurolysis is a key interventional option with demonstrated efficacy for pancreatic cancer pain.
Malignant Bowel Obstruction
Pain from malignant bowel obstruction is colicky (intermittent cramping) and/or constant (from mesenteric distension and ischemia). Management involves opioids for background pain, anticholinergics (hyoscine butylbromide 60–120 mg/day subcutaneously, or glycopyrrolate 0.6–1.2 mg/day) for colic, and corticosteroids (dexamethasone 6–16 mg/day) as an anti-inflammatory and anti-emetic adjunct. Octreotide (300–600 mcg/day subcutaneously) reduces gastrointestinal secretions.
Peritoneal Carcinomatosis
Diffuse peritoneal disease causes poorly localized abdominal pain, often with associated ascites. Pain management combines opioids, corticosteroids, and management of ascites (paracentesis for symptomatic relief).
Neuropathic Cancer Pain Syndromes
Tumor-Related Plexopathy
Brachial plexopathy (from Pancoast tumors, breast cancer, lymphoma) and lumbosacral plexopathy (from colorectal, cervical, bladder cancer, sarcoma) cause severe, progressive neuropathic pain with associated motor and sensory deficits in the affected limb distribution.
Key clinical distinction — tumor-related vs. radiation-induced plexopathy:
| Feature | Tumor-Related Plexopathy | Radiation-Induced Plexopathy |
|---|---|---|
| Pain | Severe, usually the presenting symptom | Less prominent; paresthesias and weakness may predominate |
| Onset relative to radiation | Before or without radiation history | Typically months to years after radiation (median 1.5–5 years for brachial) |
| Progression | Relatively rapid (weeks to months) | Slow (months to years) |
| Horner syndrome (brachial) | Common with Pancoast tumors | Rare |
| Imaging (MRI) | Mass or tumor infiltration visible | Diffuse tissue changes without discrete mass |
| EMG/NCS | Axonal damage pattern; may show myokymic discharges | Myokymic discharges (more common); radiation fibrosis pattern |
Malignant Epidural Spinal Cord Compression
Spinal cord compression is an oncologic emergency requiring urgent diagnosis and treatment within hours. Pain is the first symptom in approximately 95% of cases, preceding neurological deficits by weeks to months.
Warning signs requiring urgent imaging (MRI of entire spine):
- New or worsening back pain in a patient with known cancer, especially with vertebral metastases
- Radicular pain (band-like or shooting pain in a dermatomal distribution)
- Bilateral lower extremity weakness or sensory changes
- Bowel or bladder dysfunction (urinary retention, incontinence, constipation)
- Gait difficulty or ataxia
Immediate management:
- Dexamethasone 10–16 mg IV bolus, followed by 4–6 mg IV/PO every 6 hours
- Urgent MRI of the entire spine
- Radiation oncology and/or neurosurgery consultation within 24 hours
- Definitive treatment: radiation therapy, surgical decompression, or both depending on tumor type, spinal stability, neurological status, and prognosis
Treatment-Related Pain Syndromes
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
CIPN is a dose-limiting toxicity of multiple chemotherapy classes, affecting up to 68% of patients within the first month of treatment and persisting in approximately 30% of patients at 6 months or longer after completion. It is characterized by a symmetric, distal, “stocking-and-glove” distribution of sensory symptoms predominantly affecting the feet and hands. This syndrome is addressed in detail in Part 4 of this guideline.8
Post-Surgical Pain Syndromes
Chronic post-surgical pain (persisting beyond 3 months after surgery) occurs in a significant proportion of cancer surgery patients:
| Surgery | Estimated Prevalence of Chronic Pain |
|---|---|
| Mastectomy / breast-conserving surgery | 25–60% |
| Thoracotomy | 30–50% |
| Limb amputation (phantom and stump pain) | 50–85% |
| Radical neck dissection | 10–50% |
| Nephrectomy | 5–25% |
Post-surgical neuropathic pain syndromes (post-mastectomy pain syndrome, post-thoracotomy pain syndrome) result from surgical injury to intercostobrachial, intercostal, or other peripheral nerves. Management follows principles for neuropathic pain with adjuvant analgesics (gabapentinoids, duloxetine, topical lidocaine) as first-line agents.
Radiation-Related Pain
- Acute radiation mucositis/dermatitis: Inflammatory pain during and shortly after radiation; managed with topical agents, systemic analgesics
- Radiation-induced plexopathy: Delayed neuropathic pain (see above)
- Radiation-induced fibrosis: Chronic, progressive tissue fibrosis causing pain, contracture, lymphedema
- Osteoradionecrosis: Bone necrosis, particularly of the mandible after head and neck radiation
Reassessment and Documentation
Pain should be reassessed at regular intervals and after every intervention. A structured approach to reassessment includes:
- Repeat NRS or other pain intensity measure
- Assessment of functional impact (BPI interference items or targeted functional questions)
- Evaluation of analgesic regimen adherence and adverse effects
- Assessment of breakthrough pain frequency and response to rescue doses
- Psychosocial reassessment as indicated
Documentation standards:
- Pain intensity at each assessment (including worst, average, and current)
- Pain mechanism classification
- Current analgesic regimen with doses and schedule
- Breakthrough medication use (frequency, doses, efficacy)
- Adverse effects and their management
- Functional status and patient-reported pain goals
- Plan for analgesic adjustments
References
Swarm RA, Paice JA, Anghelescu DL, et al. “Adult Cancer Pain, Version 3.2019.” Journal of the National Comprehensive Cancer Network, 17(8): 977–1007, 2019. National Comprehensive Cancer Network (NCCN). DOI: 10.6004/jnccn.2019.0038. Updated through Version 1.2025. ↩︎
Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. “Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.” Pain, 94(2): 149–158, 2001. DOI: 10.1016/S0304-3959(01)00349-9 ↩︎
Wong DL, Baker CM. “Pain in children: comparison of assessment scales.” Pediatric Nursing, 14(1): 9–17, 1988. ↩︎
Cleeland CS, Ryan KM. “Pain assessment: global use of the Brief Pain Inventory.” Annals of the Academy of Medicine, Singapore, 23(2): 129–138, 1994. ↩︎
Caraceni A, Portenoy RK. “An international survey of cancer pain characteristics and syndromes.” Pain, 82(3): 263–274, 1999. DOI: 10.1016/S0304-3959(99)00073-1 ↩︎
Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. “Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review.” Pain, 153(2): 359–365, 2012. DOI: 10.1016/j.pain.2011.10.028 ↩︎
Mantyh P. “Bone cancer pain: causes, consequences, and therapeutic opportunities.” Pain, 154(suppl 1): S54–S62, 2013. DOI: 10.1016/j.pain.2013.07.044 ↩︎
Seretny M, Currie GL, Sena ES, et al. “Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.” Pain, 155(12): 2461–2470, 2014. DOI: 10.1016/j.pain.2014.09.020 ↩︎